Finance

Lists
TVRD:NASDAQ
Tvardi Therapeutics Inc
USD 1,04
-1,89%
(-0,020) 1D
13 Okt., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TVRD...
Open
USD 1,06
High
USD 1,06
Low
USD 1,01
Mkt. cap
13,87 m
Avg. vol.
204,48 k
Volume
73,45 k
52-wk high
USD 7,23
52-wk low
USD 0,93
EPS
-USD 2,78
Beta
0,37
Shares outstanding
13,34 m
No. of employees
12
Open
USD 1,06
High
USD 1,06
Low
USD 1,01
Mkt. cap
13,87 m
Avg. vol.
204,48 k
Volume
73,45 k
52-wk high
USD 7,23
52-wk low
USD 0,93
EPS
-USD 2,78
Beta
0,37
Shares outstanding
13,34 m
No. of employees
12
News stories
From web sources and news partners
About Tvardi Therapeutics Inc
CEO-
Employees12
Founded2017
HeadquartersSugar Land, Texas, Verenigde State van Amerika
SectorPharmaceutical industry
Websitetvarditherapeutics.com
Analyst ratings
Based on 6 analysts giving stock ratings to TVRD in the past 3 months
Buy
Buy
4
Hold
1
Sell
1
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for TVRD in the last 3 months.
Highest
Current USD 1,04
USD 14,00 (+1 246,15%)
Average
USD 8,20 (+688,46%)
Lowest
USD 3,00 (+188,46%)
Analyst
Recommendation
Action
Price target
Projected
Date
Debanjana Chatterjee
JonesTrading
Buy
Reiterated
USD 10,00
+861,5%
09/15/2026
Elemer Piros
Lucid Capital
Buy
Initiated
USD 14,00
+1 246,2%
09/08/2026
Sara Nik
H.C. Wainwright
Buy
Maintained
USD 9,00
+765,4%
08/21/2026
Unknown Analyst
Cantor Fitzgerald
Hold
Maintained
-
-
08/19/2026
Julian Harrison
BTIG
Buy
Maintained
USD 5,00
+380,8%
08/19/2026
Etzer Darout
Barclays
Sell
Maintained
USD 3,00
+188,5%
08/20/2026
Yasmeen Rahimi
Piper Sandler
Buy
Upgraded
USD 13,00
+1 150%
07/08/2026
Ryan Deschner
Raymond James
Buy
Upgraded
USD 10,00
+861,5%
07/08/2026
Unknown Analyst
Oppenheimer
Buy
Maintained
USD 10,00
+861,5%
05/11/2026
Jay Olson
Oppenheimer
Buy
Maintained
USD 10,00
+861,5%
05/11/2026
Steven Seedhouse
Cantor Fitzgerald
Hold
Maintained
-
-
04/01/2026
Christopher Liu
Lucid Capital
Buy
Upgraded
USD 6,00
+476,9%
02/04/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
3,60 m
5,49 m
4,91 m
4,00 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,34 m
2,10 m
2,14 m
2,63 m
Operating expense
5,94 m
7,59 m
7,05 m
6,63 m
Total operating expenses
5,94 m
7,59 m
7,05 m
6,63 m
Operating income
-5,94 m
-7,59 m
-7,05 m
-6,63 m
Other non operating income
-
-
-
-
EBT including unusual items
-5,53 m
-7,28 m
-6,80 m
-6,46 m
EBT excluding unusual items
-5,53 m
-7,28 m
-6,80 m
-6,46 m
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-5,53 m
-7,28 m
-6,80 m
-6,46 m
Net profit margin
-
-
-
-
Earnings per share
-0,59
-0,78
-0,73
-0,69
Interest and investment income
411,00 k
312,00 k
247,00 k
172,00 k
Interest expense
-
-
-
-
Net interest expenses
411,00 k
312,00 k
247,00 k
172,00 k
Depreciation and amortization charges
-
-
-
-
EBITDA
-5,91 m
-7,56 m
-7,03 m
-6,61 m
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme